17 results about "Iron deficient" patented technology

The application discloses a pentosus pentosaceus and postbiotic compound thereof for tonifying qi, nourishing face and improving anemia, and belongs to the technical field of microbial fermentation. The application screens a pentosus pentosaceus, obtains the bacterial body and postbiotic by culture, and forms a compound of the postbiotic and extract of semen ziziphi spinozae. The compound exhibits a synergistic effect, specifically, compared with the iron deficiency model group, the movement and various blood indexes of rats are improved, and are close to the normal rats of the control group. The indexes of rats in the compound group are better than those of rats fed with probiotics, and rats fed with postbiotic or semen ziziphi spinozae alone, which indicates that the compound can promote the recovery of iron content and protein indexes in the blood of rats more quickly. The application has practical value for comprehensive utilization of the pentosus pentosaceus and postbiotic, and also has important value for tonifying qi, nourishing face and improving anemia.

The present invention pertains to a combination of 2 types of inulins and nutritional compositions comprising that combination of inulins for improving the bioavailability of iron and preventing or treating iron deficiency, in particular for infants, young children, and subjects in need thereof.

In an iron (II) citrate monohydrate, identified by the formula FeC6H6O7-H2O ( Ferrous citrate monohydrate or iron citrate (II) monohydrate), obtained according to a particular production method, citric acid and elemental iron are bound in a molecular complex where the iron is agglomerated in the citrate which moves to a cyclic form and the iron is bound to the O groups of the carboxylic groups 1 and 3 through ionic bonds, forming two enantiomers, D and L (R and S), both perfectly water-soluble and highly assimilable by the human body. Formula (L) & Formula (D). With a different absorption mechanism from traditional iron molecules, said iron citrate monohydrate is usable in pharmaceutical and / or nutraceutical and / or food compositions, in particular in the treatment and prevention of iron deficiency anemias and in general of all diseases and disorders associated with iron deficiency. The effectiveness is proven by several examples.

The application belongs to the technical field of bioengineering, and provides an encoding gene for enhancing the tolerance of plants to iron deficiency stress and application thereof. The application solves the problem that soybeans are restricted in growth in an iron deficiency environment, especially in calcareous soil and soda saline-alkali soil, by mining and applying the encoding gene (nucleotide sequence as shown in SEQ ID No. 1) of a soybean GmMYB14 transcription factor. Experiments prove that the gene can significantly enhance the tolerance of plants to iron deficiency stress after overexpression in Arabidopsis thaliana and soybeans. The application provides a key gene resource for molecular breeding: GmMYB14 effectively promotes the absorption and utilization of iron in plants by regulating the phenylpropanoid metabolic pathway, which not only can improve the planting adaptability of soybeans in low-iron soil, but also can improve the yield and quality of soybeans, thereby providing strong technical support for expanding the planting area of soybeans in iron deficiency soil areas, and having important significance for relieving the insufficient production capacity of soybeans in China and improving the self-sufficiency rate.

The present application relates to a kind of kits for detecting sows' nutritional iron deficiency by biomarker quantitative detection evaluation and application, including fluorescent reaction liquid A, fluorescent reaction liquid B, internal standard, negative control, nucleic acid release agent and quantitative reference product, the fluorescent reaction liquid B contains detection primer and probe, the detection primer includes upstream primer and downstream primer, the sequence of upstream primer is 5'-ATCTGGCTTGTAAACCAACA-3', the sequence of downstream primer is 5'-ATCTTAGTTGTGGATTCCGT-3', the fluorescent reaction liquid B also contains primer probe, probe sequence is 5'-TCACCGTCAATTTCGGCTCT-3', 5' end is labeled with reporter fluorescent group, and 3' end is labeled with quenching fluorescent group.The present application effectively improves the accuracy of sows' nutritional iron deficiency detection, and provides scientific guidance for sow nutrition.

This invention discloses a kit for constructing an iron-dependent growth environment for Acinetobacter baumannii and its application method, belonging to the field of biotechnology. The kit is specifically designed for Acinetobacter baumannii, and its core components include a 50 mmol / L sterile stock solution tube of 2,2′-bipyridine, a 2000 μmol / L sterile stock solution tube of FeCl3, and a user manual. It does not include general-purpose LB medium, thus avoiding the problem of high-temperature and high-pressure deterioration of core reagents and highlighting the innovative combination of dedicated reagents. This invention also provides the application method of the kit. By adding the kit stock solution to the autoclaved and cooled LB medium in a specific ratio, standardized growth environments with normal iron, iron deficiency, and iron enrichment can be rapidly constructed. Dynamic monitoring and verification of the reversibility of growth inhibition-recovery ensure that the iron environment is precise and controllable. The kit is easy to operate, has good reproducibility, and can achieve standardized construction of the iron environment for Acinetobacter baumannii. It is suitable for iron metabolism-related research such as functional analysis of iron uptake-related proteins, development of iron deprivation antibacterial strategies, and screening of iron-deficient strains.

The present invention relates to iron complex compounds for subcutaneous use in a method of therapy, e.g., for iron deficiency, particularly of iron deficiency anaemia, in a companion animal and to pharmaceutical compositions for subcutaneous administration, comprising an iron complex compound and a pharmaceutically acceptable carrier. The present invention relates more particularly, although not exclusively, to iron octasaccharide complexes, pharmaceutical compositions comprising an iron octasaccharide complex, and the iron octasaccharide complexes for use in a method of therapy of iron deficiency, particularly of iron deficiency anaemia, in a human or non-human subject.

The invention discloses application of a rice iron deficiency tolerance gene OsIDT1 (Oryza sativa L. iron deficiency tolerance gene 1). The sequence of the iron-deficiency tolerance gene OsIDT1 is as shown in SEQ ID NO. 1. The gene can be applied in multiple aspects of promoting the iron element to be transferred from mature tissues to new tissues, improving the iron utilization efficiency of the rice and the like. The biological function of the iron-deficiency tolerance gene OsIDT1 in rice is found through a large number of experiments, and the iron element can be prevented from being transferred from a mature tissue to a new tissue by knocking out the gene, so that the iron utilization efficiency, the yield, the grain iron content and the like of the rice are reduced; the over-expression of the gene can promote the iron element to be transferred from mature tissues to new tissues, so that the iron utilization efficiency, the yield, the grain iron content and the like of the rice are improved.

The present invention relates to crystal form DCIII of compound I and a preparation method therefor, and the use of the crystal form in the preparation of a drug for treating iron deficiency-related conditions with or without iron deficiency anemia. The new crystal form of compound I provided by the present invention has the advantages of high solubility, good chemical stability, solid-state stability, mechanical stability and humidity stability, a simple preparation method, easy crystal form control, and a low production scale-up cost, etc., and is of significant value for the future development of the drug.

Injectable iron compositions comprising iron, a carbohydrate, a stabilizing agent and water are provided. These iron compositions can be prepared by mixing iron with a carbohydrate and water to form a mixture and adding a stabilizing agent to the mixture to form the stable injectable iron composition. These compositions can be considered “ready-to-use” and can treat a variety of diseases, disorders, or conditions characterized by iron deficiency or dysfunctional iron metabolism, for example, anemia.

The present invention relates to novel iron-containing pharmaceutical compositions and / or dietary supplement compositions and / or food compositions, and their use in the treatment and / or prevention of absolute or relative iron deficiency conditions in subjects in need thereof. Specifically, the present invention relates to novel compositions containing highly assimilable iron, and their use in the treatment and / or prevention of disorders and diseases associated with iron deficiency. The present invention also relates to methods for preparing said compositions.

The application discloses a strain for significantly improving HSAF yield under iron limitation and application thereof, and the genetically engineered bacterium is obtained by knocking out or silencing an iron response transcription factor Fur gene of L.enzymogenes OH11, and the nucleotide sequence of the Fur gene is shown as SEQ ID NO.1.Compared with a wild type strain, the mutant strain has no significant difference in growth in an iron deficiency or low-iron culture medium, and the HSAF synthesis capacity is greatly improved.The HSAF yield of the mutant strain in the iron deficiency culture medium reaches 162.34+5.84 mg / L, which is 3.60 times of that of the wild type strain.Therefore, the technical scheme of the application provides a more direct and effective way for improving the HSAF yield of L.enzymogenes OH11 in the iron deficiency or low-iron environment.

The application belongs to the technical field of detection, and particularly relates to a primer and kit for detecting lactobacillus reuteri and application, which comprises an upstream primer and a downstream primer, the sequence of the upstream primer is 5'-AAGCACCCTGATCCGCAAT-3', and the sequence of the downstream primer is 5'-AATTTGCCGCGCTTCGTCT-3'. The application has high sensitivity, good specificity and high precision, and can effectively detect early nutritional iron deficiency of sows.

The present invention relates to novel iron-containing pharmaceutical and / or nutraceutical and / or food compositions, and their use in the treatment and / or prevention of absolute or relative iron deficiency conditions in individuals in need thereof. Specifically, the present invention relates to novel compositions containing highly assimilable iron, and their use in the treatment and / or prevention of disorders and conditions associated with iron deficiency. The present invention also relates to methods for preparing said compositions.

The present invention relates to veterinary compositions comprising an iron complex and a water-soluble polymer as the only active ingredients. The present invention further relates to the use of such compositions for controlling iron deficiency and / or anemic conditions in non-human mammals.

Anemia, defined as a reduction in the amount of functional red blood cells in circulation, is a major cause of disease affecting one-third of the world's population. Iron is essential for hemoglobin, the functional component of red blood cells, to store and transport oxygen. Hepcidin, a liver-derived peptide, is a key regulator of iron homeostasis. During anemia, the erythropoietic hormone erythroferon regulates hepcidin synthesis to ensure an adequate supply of iron to the bone marrow for red blood cell synthesis. However, accumulating evidence suggests that other factors may perform a similar function. We identified the hepatokine FGL1 as a previously undescribed hepcidin suppressor that is highly induced in the liver in response to hypoxia during recovery from anemia and in thalassemia mice. We demonstrated that FGL1 is a potent hepcidin suppressor in vitro and in vivo. Deletion of Fgl1 in mice blunts hepcidin suppression after hemorrhage.Finally, FGL1 is a BMP antagonist that directly binds to BMP6 and impairs the BMP-SMAD signaling cascade that controls hepcidin regulation.Therefore, the present invention relates to an FGL1 polypeptide for use in treating patients suffering from iron deficiency-related diseases.

This application discloses a functional composition, a conditioning agent, and its application in the preparation of a supplement for improving sub-health conditions. The functional composition comprises a first active ingredient and a second active ingredient. The first active ingredient includes red raspberry and carrot, and the second active ingredient includes one or more of artichoke extract and Fusarium oxysporin. The mass ratio of the first active ingredient to the second active ingredient is (1-10000):(1-10000). This application, through the formulation of active ingredients, promotes the body's absorption of iron through mechanisms such as intestinal iron absorption and / or regulation of hepcidin, thereby supplementing iron and significantly improving iron deficiency. Therefore, the functional composition provided by this application can be used to improve symptoms such as anemia caused by functional iron deficiency. Simultaneously, the functional composition also has beneficial effects such as regulating constitution, replenishing qi and blood, and improving sub-health conditions.